Ignite Creation Date:
2025-12-24 @ 11:46 PM
Ignite Modification Date:
2026-01-01 @ 10:13 PM
Study NCT ID:
NCT06627751
Status:
SUSPENDED
Last Update Posted:
2025-11-17
First Post:
2024-10-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-10-02
First Submit QC Date:
None
Study First Post Date:
2024-10-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-13
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED